Effects of Qiuxieling combined with Bifidobacterium triple live powder on immune function, myocardial enzyme and C-reactive protein in children with rotavirus diarrhea

doi:10.3877/cma.j.issn.2095-2015.2024.04.015

Abstract

Abstract:

Objective

To explore the effects of Qiuxieling combined with Bifidobacterium triple live powder on immune function, myocardial enzyme indicators, and C-reactive protein (CRP) in children with rotavirus diarrhea.

Methods

A total of 120 children with rotavirus diarrhea admitted to Guangde People's Hospital from May 2020 to December 2023 were selected. They were randomly divided into a control group (n=60, receiving Bifidobacterium triple live powder) and an observation group (n=60, receiving Qiuxieling+Bifidobacterium live powder treatment) using a random number table method. The clinical efficacy of the two groups was compared, and the results and effects of immune function related indicators, myocardial enzyme indicators, and CRP of the two groups were observed and compared.

Results

After treatment, the total effective rate of clinical efficacy in the observation group was higher than that in the control group (91.67% vs.75.00% P<0.05). After treatment, serum immune function, myocardial enzyme and CRP levels in both groups were improved compared with those before treatment. The serum immune function index level in the observation group was higher than that in the control group (P<0.05), the serum myocardial enzyme index level in the observation group was lower than that in the control group (P<0.05), and the CRP level in the observation group was lower than that in the control group (P<0.05).

Conclusion

The combination of Qiuxieling and Bifidobacterium triple live powder is effective in treating children with rotavirus diarrhea, which can effectively improve their immune function, and reduce the level of myocardial enzyme and CRP.

Key words: Diarrhea, Rotavirus, Qiuxieling, Bifidobacterium triple live powder, Therapeutic effect

Min Zhou, Renqing Zhang, Xianhong Lu. Effects of Qiuxieling combined with Bifidobacterium triple live powder on immune function, myocardial enzyme and C-reactive protein in children with rotavirus diarrhea[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(04): 365-368.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2024.04.015

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2024/V14/I04/365

Figures/Tables 4

References 14

[1]	Bellandi D. Rotavirus Leads Global Diarrhea Hospitalizations Among Young Children[J]. JAMA, 2022, 328(15): 1490.
[2]	王明雯, 李静欣, 高升辉, 等. 2019年我国5岁以下腹泻住院患儿A组轮状病毒感染的流行特征分析[J]. 中华实验和临床病毒学杂志, 2022, 36(2): 172-175.
[3]	胡德强, 徐卫华, 陈婷, 等. 醒脾养儿颗粒联合双歧杆菌三联活菌散对轮状病毒腹泻患儿免疫功能、心肌酶指标和血清IL-6、CRP的影响[J]. 现代生物医学进展, 2022, 22(6): 1147-1150, 1179.
[4]	中华医学会儿科学分会消化组, 《中华儿科杂志》编辑委员会. 中国儿童急性感染性腹泻病临床实践指南[J]. 中华儿科杂志, 2016, 54(7): 483-488.
[5]	方鹤松, 魏承毓, 段恕诚, 等. "98全国腹泻病防治学术研讨会"纪要、腹泻病治疗新原则、疗效判断标准的补充建议[J]. 临床儿科杂志, 1998, 16(5): 358.
[6]	李响, 马英伟, 卢欣荣, 等. 吉林省2017—2022年腹泻婴幼儿中轮状病毒病原学特征[J]. 国际病毒学杂志, 2023, 30(5): 404-407.
[7]	李小娜, 史敏. 益生菌和蒙脱石散联合锌剂治疗轮状病毒性腹泻患儿的疗效[J]. 贵州医药, 2023, 47(6): 948-949.
[8]	陈彩华, 钟丽花, 朱道谋. 布拉酵母菌散联合蒙脱石散对轮状病毒性肠炎患儿的疗效、免疫功能及肠道微生态影响[J/OL]. 中华妇幼临床医学杂志(电子版), 2021, 17(6): 732-739.
[9]	陈岩岩, 施晨晨, 张清清, 等. 双歧杆菌三联活菌散/胶囊治疗儿童功能性消化不良的Meta分析[J]. 中国微生态学杂志, 2023, 35(6): 674-680.
[10]	刘丽君, 程莹. 消旋卡多曲与秋泻灵颗粒联合肠道微生态调节剂治疗轮状病毒性肠炎疗效及对患儿外周血T淋巴细胞亚群水平的影响[J]. 陕西医学杂志, 2020, 49(8): 1013-1015, 1039.
[11]	Fang J, Yang Y, Xie W. Chinese expert consensus on the application of live combined Bifidobacterium, Lactobacillus, and Enterococcus powder/capsule in digestive system diseases(2021)[J]. J Gastroenterol Hepatol, 2023, 38(7): 1089-1098.
[12]	海仁古丽·麦麦提, 缪梓萍, 吴焓, 等. 轮状病毒相关中枢神经系统并发症的发生机制研究进展[J]. 国际病毒学杂志, 2023, 30(1): 79-83.
[13]	路钰夏, 杨辉, 王向辉, 等. 病毒感染性腹泻对儿童人群肠道菌群IL-6, TNF-α, hs-CRP, IFN-γ水平的影响[J]. 中国实验诊断学, 2022, 26(6): 842-846.
[14]	Zhou Y, Wu J, Hu X, et al. Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms[J]. Hum Vaccin Immunother, 2023, 19(1): 2189598.

组别	例数	性别[例(%)]		年龄(岁,±s)	病程(d,±s)	脱水情况[例(%)]
组别	例数	男	女	年龄(岁,±s)	病程(d,±s)	轻度脱水	中度脱水
观察组	60	41(68.33)	19(31.67)	1.40±0.51	3.67±0.64	34(56.67)	26(43.33)
对照组	60	38(63.33)	22(36.67)	1.63±0.48	3.87±0.52	38(63.33)	22(36.67)
t/χ²		0.567		0.651	0.658	0.762
P		0.462		0.412	0.412	0.231

组别	例数	性别[例(%)]		年龄(岁,±s)	病程(d,±s)	脱水情况[例(%)]
组别	例数	男	女	年龄(岁,±s)	病程(d,±s)	轻度脱水	中度脱水
观察组	60	41(68.33)	19(31.67)	1.40±0.51	3.67±0.64	34(56.67)	26(43.33)
对照组	60	38(63.33)	22(36.67)	1.63±0.48	3.87±0.52	38(63.33)	22(36.67)
t/χ²		0.567		0.651	0.658	0.762
P		0.462		0.412	0.412	0.231

组别	例数	显效(例)	有效(例)	无效(例)	总有效率[例(%)]
观察组	60	23	32	5	55(91.67)
对照组	60	16	29	15	45(75.00)

组别	例数	显效(例)	有效(例)	无效(例)	总有效率[例(%)]
观察组	60	23	32	5	55(91.67)
对照组	60	16	29	15	45(75.00)

组别	例数	时间	IgA	IgM	IgG
观察组	60	治疗前	0.47±0.09	0.77±0.19	5.94±0.77
观察组	60	治疗后	0.89±0.12^a	1.06±0.14^a	9.69±0.92^a
对照组	60	治疗前	0.50±0.10	0.72±0.11	6.07±0.80
对照组	60	治疗后	0.69±0.15^a	0.88±0.17^a	7.51±0.89^a
t组间治疗后			6.154	4.542	8.591
P组间治疗后			0.004	0.008	0.001

Please choose a citation manager

Content to export